Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06627244 · ClinicalTrials.gov registry record · Phase 2

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

A Phase 2 study of Metastatic Uveal Melanoma and Metastatic Uveal Melanoma in the Liver, sponsored by University of Miami.

Recruiting
Registry status
Phase 2
Development phase
30
Enrollment target
1
Study location

NCT06627244: Recruiting Phase 2 study of Metastatic Uveal Melanoma and Metastatic Uveal Melanoma in the Liver, sponsored by University of Miami.

NCT06627244 is a Phase 2 study of Metastatic Uveal Melanoma and Metastatic Uveal Melanoma in the Liver that is actively recruiting participants, run by University of Miami. The registered enrollment target is 30 participants, below the 130-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06627244, a Phase 2 study of Metastatic Uveal Melanoma and Metastatic Uveal Melanoma in the Liver, is actively recruiting participants, sponsored by University of Miami.

RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the effects (good and bad) that Tebentafusp in combination with Yttrium-90 (Y-90) radioembolization has on patients with metastatic uveal melanoma that has spread to the liver.

Primary Outcome

Progression-free survival (PFS) will be defined as the elapsed time in months from the first date of study treatment until documented disease progression, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or death from any cause, whichever is earlier. For participants who remain alive without progression, follow-up time will be censored at the date of last disease assessment.

Conditions Studied

Metastatic Uveal Melanoma Metastatic Uveal Melanoma in the Liver

Interventions

  • RADIATION TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
  • DRUG Tebentafusp

Study Locations (1)

Florida

  • University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-02-14
Est. Completion 2031-02-17
Phase Phase 2
University of Miami

721 total trials

What NCT06627244 shows while recruiting

NCT06627244 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 130-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (77% lower).

The record links to 2 conditions, with Metastatic Uveal Melanoma appearing as the primary indexed condition, and to 2 interventions - of which TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization is the first listed.

NCT06627244 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT06627244 about?

NCT06627244 is a clinical study titled "Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma". The purpose of this study is to determine the effects (good and bad) that Tebentafusp in combination with Yttrium-90 (Y-90) radioembolization has on patients with metastatic uveal melanoma that has spread to the liver.

What is the current status of trial NCT06627244?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-02-14. Estimated completion is 2031-02-17.

What conditions does trial NCT06627244 study?

This clinical trial studies the following conditions: Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver.

What interventions are being tested in trial NCT06627244?

The interventions under investigation include: TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization (RADIATION), Tebentafusp (DRUG).

Who is sponsoring clinical trial NCT06627244?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06627244 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Uveal Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06627244's enrollment target sits among peer trials

30 11th of 14 higher than 3 of 14 other Metastatic Uveal Melanoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Uveal Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06627244

Source: ClinicalTrials.gov NCT06627244, the US trial registry maintained by the National Library of Medicine. NCT06627244 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.